Clear guidance on hysterectomy, salpingectomy and risk-reducing ovary or breast surgery, including who may benefit and what must be considered.
Surgery can reduce cancer risk in carefully selected situations, but every organ removed also has reproductive, hormonal and surgical consequences. Decisions should start with a verified diagnosis or inherited-risk assessment—not fear alone.
A hysterectomy removes the uterus and may be appropriate for cancer, precancer or severe benign disease after alternatives are considered. It is not routinely recommended to prevent gynaecological cancer in an average-risk person. Removing the uterus, tubes and ovaries are separate decisions.
Hysterectomy may treat cancer, endometrial precancer, uncontrollable bleeding, fibroids, adenomyosis, prolapse or other significant disease. The indication determines whether the cervix, tubes or ovaries are also considered.
For someone already undergoing suitable pelvic surgery or choosing permanent sterilisation, removing both fallopian tubes may reduce future epithelial ovarian-cancer risk without removing the ovaries.
Risk-reducing salpingo-oophorectomy may be recommended for confirmed BRCA1/2 or selected other high-risk syndromes after specialist genetic counselling and family completion.
Bilateral risk-reducing mastectomy is an option for some people with a high-risk pathogenic variant or exceptional family history, usually through a specialist breast and genetics team.
Usually not for an average-risk person. It may be indicated for cancer, precancer or severe benign disease, and can be part of risk reduction for selected inherited syndromes after specialist counselling.
No. Hysterectomy removes the uterus. Salpingectomy removes the tubes and oophorectomy removes ovaries. Each should be discussed separately because the effects differ.
Removing both tubes during another appropriate pelvic operation may reduce risk, but it does not eliminate it. The decision must consider fertility, permanence and the original reason for surgery.
